MilliporeSigma
  • Home
  • Search Results
  • Urinary tract analgesics for the treatment of patients with acute cystitis: where is the clinical evidence?

Urinary tract analgesics for the treatment of patients with acute cystitis: where is the clinical evidence?

Expert review of anti-infective therapy (2012-10-04)
Vassilis Pergialiotis, Pantelis Arnos, Michael N Mavros, Eleni Pitsouni, Stavros Athanasiou, Matthew E Falagas
ABSTRACT

Acute cystitis is one of the most common health-related problems in the female population. Over the last few decades, a number of drugs labeled as 'urinary tract analgesics' were released; these are available over the counter and are gaining widespread resonance among the North American population. The main representatives of this class of drugs are phenazopyridine and methenamine hippurate. Methenamine's efficacy and side effects have been well studied in a recent systematic review. On the other hand, in contrast to its widespread use, the published clinical evidence regarding phenazopyridine's effectiveness and safety is scarce. In addition, consumers (potentially patients) appear to ignore the limitations of this kind of treatment. In this article, concerns regarding the use of over-the-counter uroanalgesics, with a focus on the relevant clinical evidence, are discussed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hexamethylenetetramine, ReagentPlus®, 99%
Sigma-Aldrich
Hexamethylenetetramine, ACS reagent, ≥99.0%
Sigma-Aldrich
Hexamethylenetetramine, meets analytical specification of Ph. Eur., BP, 99-100.5% (calc. to the dried substance)
Sigma-Aldrich
Hexamethylenetetramine, puriss. p.a., reag. Ph. Eur., ≥99.5% (calc. to the dried substance)
Methenamine, European Pharmacopoeia (EP) Reference Standard
Supelco
Hexamethylenetetramine